Randomized Controlled Trial of High-Flow Nasal Cannula in Preterm Infants After Extubation

Area of Science:

• Neonatal respiratory support
• Pediatric critical care
• Pulmonary medicine

Background:

• Preterm infants often require noninvasive ventilation after extubation.
• High-flow nasal cannula (HFNC) is an alternative to traditional methods like NCPAP/NIPPV.
• Efficacy of HFNC versus NCPAP/NIPPV in this population requires clear comparison.

Purpose of the Study:

• To compare the efficacy and safety of HFNC versus NCPAP/NIPPV post-extubation in preterm infants.
• To identify factors associated with treatment failure when using HFNC.

Main Methods:

• Prospective, randomized, noninferiority trial in 6 tertiary NICUs.
• Infants born at <34 weeks requiring noninvasive ventilation post-extubation were randomized.
• Primary outcome: treatment failure within 7 days post-extubation.

Main Results:

• Treatment failure occurred in 31% of the HFNC group vs. 16% of the NCPAP/NIPPV group.
• HFNC demonstrated a significantly higher rate of treatment failure (risk difference: 14.9%).
• Histologic chorioamnionitis, treated patent ductus arteriosus, and younger corrected gestational age were linked to HFNC failure.

Conclusions:

• HFNC showed a significantly higher treatment failure rate compared to NCPAP or NIPPV in preterm infants post-extubation.
• Histologic chorioamnionitis, treated patent ductus arteriosus, and younger corrected gestational age are independent factors associated with HFNC treatment failure.